Suven Life Sciences, has been granted patent for the treatment of disorders related with neurodegenerative diseases, by Singapore corresponding to the New Chemical Entities (NCEs).
In a BSE filing the company stated that, the patents are valid till 2033.
As per Venkat Jasti, Suven Life CEO,”We are very pleased by the grant of these patents to Suven for our pipeline of molecules in the CNS arena, which are being developed for cognitive disorders with high unmet medical need with a huge market potential globally.”
